tiprankstipranks
Trending News
More News >
Syndax Pharmaceuticals Inc. (SNDX)
:SNDX
US Market
Advertisement

Syndax Pharmaceuticals (SNDX) Stock Forecast & Price Target

Compare
749 Followers
See the Price Targets and Ratings of:

SNDX Analyst Ratings

Strong Buy
11Ratings
Strong Buy
10 Buy
1 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Syndax
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SNDX Stock 12 Month Forecast

Average Price Target

$35.10
▲(179.24% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Syndax Pharmaceuticals in the last 3 months. The average price target is $35.10 with a high forecast of $56.00 and a low forecast of $17.00. The average price target represents a 179.24% change from the last price of $12.57.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","32":"$32","57":"$57","19.5":"$19.5","44.5":"$44.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$56.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,19.5,32,44.5,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.98,13.52,17.06,20.6,24.14,27.68,31.22,34.76,38.3,41.839999999999996,45.379999999999995,48.92,52.459999999999994,{"y":56,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.98,11.912307692307692,13.844615384615384,15.776923076923078,17.70923076923077,19.64153846153846,21.573846153846155,23.506153846153847,25.43846153846154,27.37076923076923,29.303076923076922,31.235384615384614,33.167692307692306,{"y":35.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.98,10.52,11.06,11.6,12.14,12.68,13.219999999999999,13.76,14.3,14.84,15.379999999999999,15.92,16.46,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.55,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.89,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.7,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.22,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.17,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.01,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.82,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.98,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$56.00Average Price Target$35.10Lowest Price Target$17.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
$46$51
Buy
305.73%
Upside
Reiterated
08/05/25
Citi ups Syndax target, opens 'upside catalyst watch'Citi ups Syndax target, opens 'upside catalyst watch'
BTIG
$43$56
Buy
345.51%
Upside
Reiterated
08/05/25
Syndax price target raised to $56 from $43 at BTIGSyndax price target raised to $56 from $43 at BTIG
Goldman Sachs Analyst forecast on SNDX
Corinne JohnsonGoldman Sachs
Goldman Sachs
$18$20
Buy
59.11%
Upside
Reiterated
08/05/25
Syndax Pharmaceuticals (SNDX) Gets a Buy from Goldman Sachs
Scotiabank Analyst forecast on SNDX
George FarmerScotiabank
Scotiabank
$17
Hold
35.24%
Upside
Reiterated
08/05/25
Syndax Pharmaceuticals (SNDX) Gets a Hold from Scotiabank
TD Cowen Analyst forecast on SNDX
Phil NadeauTD Cowen
TD Cowen
Buy
Reiterated
08/04/25
Syndax Pharmaceuticals: Strong Performance and Growth Potential Justify Buy Rating
Barclays Analyst forecast on SNDX
Peter LawsonBarclays
Barclays
$19
Buy
51.15%
Upside
Reiterated
07/30/25
Barclays Sticks to Its Buy Rating for Syndax Pharmaceuticals (SNDX)
UBS
$37$35
Buy
178.44%
Upside
Reiterated
07/15/25
Syndax price target lowered to $35 from $37 at UBSSyndax price target lowered to $35 from $37 at UBS
Bank of America Securities Analyst forecast on SNDX
Jason ZemanskyBank of America Securities
Bank of America Securities
$26
Buy
106.84%
Upside
Reiterated
06/12/25
Bank of America Securities Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)
Jefferies Analyst forecast on SNDX
Kelly ShiJefferies
Jefferies
$43
Buy
242.08%
Upside
Reiterated
06/05/25
Syndax Pharmaceuticals: Promising 2025 Outlook and Strategic Product Launches Drive Buy Rating
J.P. Morgan Analyst forecast on SNDX
Anupam RamaJ.P. Morgan
J.P. Morgan
$41$39
Buy
210.26%
Upside
Reiterated
05/23/25
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (NASDAQ: SNDX) and Doximity (NYSE: DOCS)
Mizuho Securities Analyst forecast on SNDX
Salim SyedMizuho Securities
Mizuho Securities
$45
Buy
258.00%
Upside
Reiterated
05/16/25
Mizuho Securities Keeps Their Buy Rating on Syndax Pharmaceuticals (SNDX)
H.C. Wainwright Analyst forecast on SNDX
Edward WhiteH.C. Wainwright
H.C. Wainwright
$51
Buy
305.73%
Upside
Reiterated
03/04/25
Analysts Are Bullish on Top Healthcare Stocks: Artelo Biosciences (ARTL), Syndax Pharmaceuticals (SNDX)
B.Riley Financial Analyst forecast on SNDX
Kalpit PatelB.Riley Financial
B.Riley Financial
$36$29
Buy
130.71%
Upside
Reiterated
03/03/25
Syndax price target lowered to $29 from $36 at B. RileySyndax price target lowered to $29 from $36 at B. Riley
Stifel Nicolaus Analyst forecast on SNDX
Bradley CaninoStifel Nicolaus
Stifel Nicolaus
$42
Buy
234.13%
Upside
Reiterated
01/31/25
Stifel Nicolaus Keeps Their Buy Rating on Syndax Pharmaceuticals (SNDX)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
$46$51
Buy
305.73%
Upside
Reiterated
08/05/25
Citi ups Syndax target, opens 'upside catalyst watch'Citi ups Syndax target, opens 'upside catalyst watch'
BTIG
$43$56
Buy
345.51%
Upside
Reiterated
08/05/25
Syndax price target raised to $56 from $43 at BTIGSyndax price target raised to $56 from $43 at BTIG
Goldman Sachs Analyst forecast on SNDX
Corinne JohnsonGoldman Sachs
Goldman Sachs
$18$20
Buy
59.11%
Upside
Reiterated
08/05/25
Syndax Pharmaceuticals (SNDX) Gets a Buy from Goldman Sachs
Scotiabank Analyst forecast on SNDX
George FarmerScotiabank
Scotiabank
$17
Hold
35.24%
Upside
Reiterated
08/05/25
Syndax Pharmaceuticals (SNDX) Gets a Hold from Scotiabank
TD Cowen Analyst forecast on SNDX
Phil NadeauTD Cowen
TD Cowen
Buy
Reiterated
08/04/25
Syndax Pharmaceuticals: Strong Performance and Growth Potential Justify Buy Rating
Barclays Analyst forecast on SNDX
Peter LawsonBarclays
Barclays
$19
Buy
51.15%
Upside
Reiterated
07/30/25
Barclays Sticks to Its Buy Rating for Syndax Pharmaceuticals (SNDX)
UBS
$37$35
Buy
178.44%
Upside
Reiterated
07/15/25
Syndax price target lowered to $35 from $37 at UBSSyndax price target lowered to $35 from $37 at UBS
Bank of America Securities Analyst forecast on SNDX
Jason ZemanskyBank of America Securities
Bank of America Securities
$26
Buy
106.84%
Upside
Reiterated
06/12/25
Bank of America Securities Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX)
Jefferies Analyst forecast on SNDX
Kelly ShiJefferies
Jefferies
$43
Buy
242.08%
Upside
Reiterated
06/05/25
Syndax Pharmaceuticals: Promising 2025 Outlook and Strategic Product Launches Drive Buy Rating
J.P. Morgan Analyst forecast on SNDX
Anupam RamaJ.P. Morgan
J.P. Morgan
$41$39
Buy
210.26%
Upside
Reiterated
05/23/25
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (NASDAQ: SNDX) and Doximity (NYSE: DOCS)
Mizuho Securities Analyst forecast on SNDX
Salim SyedMizuho Securities
Mizuho Securities
$45
Buy
258.00%
Upside
Reiterated
05/16/25
Mizuho Securities Keeps Their Buy Rating on Syndax Pharmaceuticals (SNDX)
H.C. Wainwright Analyst forecast on SNDX
Edward WhiteH.C. Wainwright
H.C. Wainwright
$51
Buy
305.73%
Upside
Reiterated
03/04/25
Analysts Are Bullish on Top Healthcare Stocks: Artelo Biosciences (ARTL), Syndax Pharmaceuticals (SNDX)
B.Riley Financial Analyst forecast on SNDX
Kalpit PatelB.Riley Financial
B.Riley Financial
$36$29
Buy
130.71%
Upside
Reiterated
03/03/25
Syndax price target lowered to $29 from $36 at B. RileySyndax price target lowered to $29 from $36 at B. Riley
Stifel Nicolaus Analyst forecast on SNDX
Bradley CaninoStifel Nicolaus
Stifel Nicolaus
$42
Buy
234.13%
Upside
Reiterated
01/31/25
Stifel Nicolaus Keeps Their Buy Rating on Syndax Pharmaceuticals (SNDX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Syndax Pharmaceuticals

1 Month
xxx
Success Rate
7/15 ratings generated profit
47%
Average Return
+0.31%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 46.67% of your transactions generating a profit, with an average return of +0.31% per trade.
3 Months
xxx
Success Rate
6/15 ratings generated profit
40%
Average Return
-2.86%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of -2.86% per trade.
1 Year
Success Rate
6/15 ratings generated profit
40%
Average Return
-13.41%
reiterated a buy rating 2 days ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -13.41% per trade.
2 Years
xxx
Success Rate
3/13 ratings generated profit
23%
Average Return
-25.00%
reiterated a xxx
rating yesterday
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 23.08% of your transactions generating a profit, with an average return of -25.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SNDX Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
12
16
12
16
12
Buy
2
4
3
4
3
Hold
3
4
2
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
24
17
21
16
In the current month, SNDX has received 15 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. SNDX average Analyst price target in the past 3 months is 35.10.
Each month's total comprises the sum of three months' worth of ratings.

SNDX Financial Forecast

SNDX Earnings Forecast

Next quarter’s earnings estimate for SNDX is -$0.72 with a range of -$0.96 to -$0.54. The previous quarter’s EPS was -$0.83. SNDX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year SNDX has Preformed in-line its overall industry.
Next quarter’s earnings estimate for SNDX is -$0.72 with a range of -$0.96 to -$0.54. The previous quarter’s EPS was -$0.83. SNDX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year SNDX has Preformed in-line its overall industry.

SNDX Sales Forecast

Next quarter’s sales forecast for SNDX is $47.62M with a range of $36.00M to $60.17M. The previous quarter’s sales results were $37.96M. SNDX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year SNDX has Preformed in-line its overall industry.
Next quarter’s sales forecast for SNDX is $47.62M with a range of $36.00M to $60.17M. The previous quarter’s sales results were $37.96M. SNDX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.64% of the time in the same period. In the last calendar year SNDX has Preformed in-line its overall industry.

SNDX Stock Forecast FAQ

What is SNDX’s average 12-month price target, according to analysts?
Based on analyst ratings, Syndax Pharmaceuticals Inc.’s 12-month average price target is 35.10.
    What is SNDX’s upside potential, based on the analysts’ average price target?
    Syndax Pharmaceuticals Inc. has 179.24% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SNDX a Buy, Sell or Hold?
          Syndax Pharmaceuticals Inc. has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Syndax Pharmaceuticals Inc.’s price target?
            The average price target for Syndax Pharmaceuticals Inc. is 35.10. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $56.00 ,the lowest forecast is $17.00. The average price target represents 179.24% Increase from the current price of $12.57.
              What do analysts say about Syndax Pharmaceuticals Inc.?
              Syndax Pharmaceuticals Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of SNDX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis